← All trials
NCT06326723
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2023
- Primary completion
- Dec 24, 2023
- Completion date
- Feb 5, 2024
- First posted
- Mar 22, 2024
- Last posted
- Mar 22, 2024
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Simcere Pharmaceutical Co., LtdLead sponsor
- Nanjing UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.